Under Diagnosis and Over Diagnosis of Prostate Cancer in a Screening Population With Serum PSA 2 to 10 ng/ml

Journal of Urology

Volumn 178, Issue 1, 2007, Pages 93-97

  Pelzer, Alexandre E ^a   Bektic, Jasmin ^a   Akkad, Thomas ^a   Ongarello, Stefano ^c,d   Schaefer, Georg ^b   Schwentner, Christian ^a   Frauscher, Ferdinand ^a   Bartsch, Georg ^a   Horninger, Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

diagnosis; mass screening; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER SIZE; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AGED; AUSTRIA; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 34250170858     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.03.021     Document Type: Article

References (19)

1. Catalona W.J., Smith D.S., Ratliff T.L., and Basler J.W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270 (1993) 948
2. Feuer E.J., Merrill R.M., and Hankey B.F. Cancer surveillance series: interpreting trends in prostate cancer-part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 91 (1999) 1025
3. Etzioni R., Legler J.M., Feuer E.J., Merrill R.M., Cronin K.A., and Hankey B.F. Cancer surveillance series: interpreting trends in prostate cancer-part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 91 (1999) 1033
4. Newschaffer C.J., Otani K., McDonald M.K., and Penberthy L.T. Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. J Natl Cancer Inst 92 (2000) 613
5. Epstein J.I., Walsh P.C., Carmichael M., and Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368
6. Bartsch G., Horninger W., Klocker H., Reissigl A., Oberaigner W., Schonitzer D., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58 (2001) 417
7. Oesterling J.E., Kumamoto Y., Tsukamoto T., Girman C.J., Guess H.A., Masumori N., et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol 75 (1995) 347
8. Pelzer A., Bektic J., Berger A.P., Pallwein L., Halpern E.J., Horninger W., et al. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol 173 (2005) 1926
9. Horninger W., Berger A.P., Rogatsch H., Gschwendtner A., Steiner H., Niescher M., et al. Characteristics of prostate cancers detected at low PSA levels. Prostate 58 (2004) 232
10. Etzioni R., Penson D.F., Legler J.M., di Tommaso D., Boer R., Gann P.H., et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94 (2002) 981
11. McGregor M., Hanley J.A., Boivin J.F., and McLean R.G. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 159 (1998) 1368
12. Han M., Partin A.W., Pound C.R., Epstein J.I., and Walsh P.C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28 (2001) 555
13. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
14. Sweat S.D., Bergstralh E.J., Slezak J., Blute M.L., and Zincke H. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 168 (2002) 525
15. Johansson J.E., Andren O., Andersson S.O., Dickman P.W., Holmberg L., Magnuson A., et al. Natural history of early, localized prostate cancer. JAMA 291 (2004) 2713
16. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095
17. Bill-Axelson A., Holmberg L., Ruutu M., Haggman M., Andersson S.O., Bratell S., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977
18. Draisma G., Boer R., Otto S.J., vanderCruijsen I.W., Damhuis R.A., Schroder F.H., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868
19. Pettus J.A., Weight C.J., Thompson C.J., Middleton R.G., and Stephenson R.A. Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location. J Urol 172 (2004) 129